Lilly Crushes Q2 Estimates, Raises Outlook as Mounjaro and Zepbound Rake in $14.9B
LLY sits 85% above its 52-week low of $623.78.
Summary
Eli Lilly delivered a massive Q2 beat, with adjusted EPS of $8.38 trouncing the $6.01 consensus and revenue surging 48% to $22.97B. The obesity and diabetes franchise remains the juggernaut — Mounjaro and Zepbound alone generated $14.9B, adding $6.3B year-over-year. Management raised the full-year revenue guide to $85B-$87B, above the Street's $85.45B, and tightened EPS guidance to $35.50-$36.50. The quarter also brought a CVS Health collaboration for transparent Zepbound/Foundayo pricing and an FDA Breakthrough Therapy nod for olomorasib in pancreatic cancer. This follows a string of positive clinical data for retatrutide and Foundayo, reinforcing Lilly's dominance in the GLP-1 space. The raised guidance and pipeline momentum suggest the growth story is far from priced in.
At the time of this announcement, LLY was trading at $1,156.57 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Benzinga.